Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Today in Healthcare.
Bioma Probiotics Launches Science-Backed Gut Health Formula for Women’s Natural Weight Loss
GlobeNewswire, Inc.
·
August 5, 2025
New York City, NY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Weight loss is more than calories in versus calories out—it’s a battle that often begins in the gut. Millions of people, particularly women, face a frustrating cycle of dieting, fatigue, and...
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
GlobeNewswire, Inc.
·
August 5, 2025
SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and...
Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico
GlobeNewswire, Inc.
·
August 5, 2025
MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has...
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
GlobeNewswire, Inc.
·
July 8, 2025
Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trial In Group 1 (n=24), kidney function stabilized in patients randomized to receive two...
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
GlobeNewswire, Inc.
·
July 8, 2025
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for verekitug into third indication, strengthening...
HIMS CLASS ACTION: Hims & Hers Health, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by August 25 Legal Deadline (NYSE:HIMS)
GlobeNewswire, Inc.
·
August 5, 2025
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential...
Ethiopian government is to widen access to healthcare services
MENAFN
·
July 7, 2025
(MENAFN) The Ethiopian government has announced what it describes as major strides in widening access to healthcare services across the country. Speaking at a public health forum in Addis Ababa on Saturday, the country’s health minister, Mekdes...
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman
GlobeNewswire, Inc.
·
August 4, 2025
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients...
Beacon Healthcare Systems Names Mark Vo as Chief Technology Officer - DELETED
EIN Presswire
·
August 4, 2025
HUNTINGTON BEACH, CA, UNITED STATES, August 4, 2025 /EINPresswire.com/ -- Beacon Names Mark Vo as Chief Technology Officer to Drive Next Phase of Growth and Innovation Beacon Healthcare Systems, a leading provider of innovative healthcare...
British Columbians Want a Future Worth Staying For
GlobeNewswire, Inc.
·
August 5, 2025
Vancouver, B.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- The Business Council of British Columbia (BCBC) today released an update summarizing the results of its Stay With B.C. campaign — a province-wide initiative that heard from more than 3,000 British...
Duos Edge AI Hosts Congressman Ronny Jackson’s Staff at Amarillo Edge Data Center
GlobeNewswire, Inc.
·
August 5, 2025
JACKSONVILLE, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT), through its operating subsidiary Duos Edge AI, Inc. (“Duos Edge AI”), a provider of adaptive, versatile and streamlined...
Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
GlobeNewswire, Inc.
·
August 5, 2025
All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well tolerated Company expects to initiate Phase 1b study with CDI-988 in norovirus-infected healthy subjects later this year Lack of approved norovirus treatments or...
electroCore Appoints James C. Theofilos to the Board of Directors
GlobeNewswire, Inc.
·
August 5, 2025
ROCKAWAY, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that James C. Theofilos has been appointed to the Board of Directors, effective...
Ipsos strengthens its expertise in Germany with the acquisition of InMoment's Healthcare division
GlobeNewswire, Inc.
·
July 7, 2025
Ipsos strengthens its expertise in Germany with the acquisition of InMoment's Healthcare division Paris, 7 July 2025 - Ipsos, one of the world's leading market research companies, announces the acquisition of InMoment’s Healthcare division in...
Solutionreach Celebrates 25 Years of Healthcare SaaS Innovation
EIN Presswire
·
July 7, 2025
Digital Patient Communication Pioneer Readies Itself For A New Era LEHI, UT, UNITED STATES, July 7, 2025 /EINPresswire.com/ -- Utah-based healthcare SaaS brand Solutionreach is celebrating 25 years of innovation and leadership in the healthcare...
SynOx Therapeutics Completes Enrollment in Registrational Phase 3 TANGENT Clinical Trial Significantly Ahead of Timeline
GlobeNewswire, Inc.
·
August 5, 2025
DUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today...
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115
GlobeNewswire, Inc.
·
August 5, 2025
LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met the study’s primary objectives New NPM-139...
Flare Therapeutics Announces Initiation of Phase 1B Study of FX-909 for Treatment of Metastatic Urothelial Cancer
GlobeNewswire, Inc.
·
August 5, 2025
CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced...
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results
GlobeNewswire, Inc.
·
August 5, 2025
Reported positive top-line results from SUMMIT evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis, achieving statistical significance across all primary and key secondary endpoints On track to share pivotal trial results...
Global Ship Lease Reports Results for the Second Quarter of 2025
GlobeNewswire, Inc.
·
August 5, 2025
Forward contract cover locked in for 96% of 2025 days and 80% of 2026 days Maximizing strategic optionality while also returning capital to shareholders via annualized dividend of $2.10 per Class A Common Share ATHENS, Greece, Aug. 05, 2025 (GLOBE...